DE vs LLY: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Deere & Company · Industrials
$589.24
-29.6% upside to fair value
Grade D
High Quality
VS
Eli Lilly and Company · Healthcare
$1,098.13
+16.7% upside to fair value
Grade B
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+16.7%).
DE trades at a lower forward P/E
(33.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
LLY |
| Current Price |
$589.24 |
$1,098.13 |
| Fair Value Estimate |
$414.61 |
$1,281.02 |
| Upside to Fair Value |
-29.6%
|
+16.7%
|
| Market Cap |
$159.1B |
$1,034.2B |
| Forward P/E |
33.3x
|
38.9x
|
| EV / EBITDA |
18.8x
|
32.0x
|
| Price / Sales |
3.4x
|
14.3x
|
| Price / FCF |
42.2x
|
76.2x
|
| Revenue Growth YoY |
+6.7%
|
+55.5%
|
| Gross Margin |
35.4%
|
83.5%
|
| Operating Margin |
18.4%
|
45.9%
|
| Return on Equity |
18.3%
|
101.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.37%
|
1.31%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Deere & Company is a leading global manufacturer of agricultural, construction, and forestry machinery with a durable competitive moat anchored by its number one market share in large agricultural equipment and a dense dealer network. The company benefits from embedded precision agriculture technology that widens its competitive gap, particularly in North America where it holds 40 to 60 percent m…
Eli Lilly and Company is a leading healthcare firm specializing in drug manufacturing with a strong competitive moat in GLP-1 diabetes and obesity treatments as well as biologics manufacturing. The company is led by experienced internal management with a proven capital allocation track record. Its revenue growth is exceptionally strong, driven by its cardiometabolic franchise which accounted for …
Accumulation Zones
| Metric |
DE |
LLY |
| Zone Low |
$310.96 |
$960.76 |
| Zone High |
$352.42 |
$1,088.87 |
| In Buy Zone? |
No
|
No
|